Trade Hikma Pharmaceuticals PLC - HIK CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.42 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.025295% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.003377% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 18.58 |
| Open | 18.51 |
| 1-Year Change | -9.4% |
| Day's Range | 18.45 - 18.84 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 18.54 | 0.24 | 1.31% | 18.30 | 18.63 | 18.25 |
| Jul 24, 2024 | 18.52 | 0.08 | 0.43% | 18.44 | 18.65 | 18.20 |
| Jul 23, 2024 | 18.55 | -0.04 | -0.22% | 18.59 | 18.70 | 18.31 |
| Jul 22, 2024 | 18.48 | -0.12 | -0.65% | 18.60 | 18.87 | 18.46 |
| Jul 19, 2024 | 18.61 | 0.23 | 1.25% | 18.38 | 18.67 | 18.16 |
| Jul 18, 2024 | 18.52 | 0.02 | 0.11% | 18.50 | 18.68 | 18.40 |
| Jul 17, 2024 | 18.54 | 0.18 | 0.98% | 18.36 | 18.59 | 18.16 |
| Jul 16, 2024 | 18.34 | 0.15 | 0.82% | 18.19 | 18.48 | 18.03 |
| Jul 15, 2024 | 18.32 | 0.30 | 1.66% | 18.02 | 18.94 | 17.89 |
| Jul 12, 2024 | 18.08 | -0.34 | -1.85% | 18.42 | 18.42 | 18.08 |
| Jul 11, 2024 | 18.24 | 0.29 | 1.62% | 17.95 | 18.27 | 17.95 |
| Jul 10, 2024 | 17.88 | -0.15 | -0.83% | 18.03 | 18.21 | 17.88 |
| Jul 9, 2024 | 17.91 | -0.17 | -0.94% | 18.08 | 18.27 | 17.91 |
| Jul 8, 2024 | 18.13 | 0.10 | 0.55% | 18.03 | 18.23 | 18.03 |
| Jul 5, 2024 | 18.13 | -0.21 | -1.15% | 18.34 | 18.48 | 17.99 |
| Jul 4, 2024 | 18.31 | 0.04 | 0.22% | 18.27 | 18.42 | 18.12 |
| Jul 3, 2024 | 18.21 | -0.28 | -1.51% | 18.49 | 18.55 | 18.03 |
| Jul 2, 2024 | 18.37 | -0.14 | -0.76% | 18.51 | 18.63 | 18.18 |
| Jul 1, 2024 | 18.68 | -0.11 | -0.59% | 18.79 | 18.91 | 18.55 |
| Jun 28, 2024 | 18.84 | 0.10 | 0.53% | 18.74 | 18.92 | 18.68 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Hikma Company profile
Discover the latest Hikma share price today with our comprehensive live chart.
Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.
Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.
Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.
Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.
Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.
The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.
In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.
The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.
Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017.
According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).
Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.
| Industry: | Pharmaceuticals (NEC) |
1 New Burlington Place
LONDON
W1S 2HR
GB
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com